Halting hepatocellular carcinoma: Identifying intercellular crosstalk in HBV-driven disease

作者：Lingyun Zhou, Chang‐Hai Liu, Duoduo Lv, Klarke M. Sample, Ángela Rojas, Yugu Zhang, Huandi Qiu, Linye He, Li Zheng, Liyu Chen, Binru Cai, Yiguo Hu, Manuel Romero‐Gómez · 发表于：Cell Reports · 年份：2025 · DOI：10.1016/j.celrep.2025.115457 · 被引用次数：14 · 研究领域：Hepatitis B Virus Studies、Liver Disease Diagnosis and Treatment、Cancer-related Molecular Pathways

Hepatitis B infection can lead to liver fibrosis and hepatocellular carcinoma (HCC). Despite antiviral therapies, some patients still develop HCC. This study investigates hepatitis B virus (HBV)-induced hepatocyte-hepatic stellate cell (HSC) crosstalk and its role in liver fibrosis and HCC. Using MYC-driven liver cancer stem cell organoids, HCC-patient-derived xenograft (PDX) models, and HBV replication models, this study reveals that HBV transcription affected hepatocyte development, activated the DNA repair pathway, and promoted glycolysis. HBV activated nicotinamide phosphoribosyltransferase (NAMPT) through DNA damage receptor ATR. NAMPT-insulin receptor (INSR)-mediated hepatocyte-HSC crosstalk caused HSCs to develop a myofibroblast phenotype and activated telomere maintenance mechanisms via PARP1 multisite lactylation. Inhibition of the ATR-NAMPT-INSR-PARP1 pathway effectively blocks HBV-induced liver fibrosis and HCC progression. Targeting this pathway could be a promising strategy for chronic HBV infection management.